1. be = 18 years of age on the day of signing of informed consent.
2. have a life expectancy of at least 3 months.
3. have histologically or cytologically confirmed Stage 4 NSCLC (squamous or nonsquamous) and be considered for standard therapy with pembrolizumab and chemotherapy.
4. have confirmation that mutation-directed therapy is not indicated (documentation of absence of tumor activating mutations/fusions that are approved for first line therapy).
5. have at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined by the local site Investigator/radiology assessment.

1. does not have predominantly squamous cell or nonsquamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.
2. is currently participating in or has participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001.
Note: Participants cannot have received prior therapy for NSCLC (see Inclusion Criteria #6).
3. prior to the first dose of EIK1001, has received prior systemic therapy for metastatic disease, or had major surgery (< 3 weeks prior to the first dose).
4. has received a live-virus vaccination within 30 days of the start of treatment initiation.
5. has received radiation therapy to the lung that is > 30 Gy within 6 months of the first dose of study drug administration.

• Oncology (Adult)

• Eikon Therapeutics